Objective: 3-Methylcholanthrene (MC), a polycylic aromatic hydrocarbon, induces atherogenesis in mice fed an atherogenic diet. In this study, we tested the hypothesis that MC would induce DNA adducts in mouse aortic smooth muscle cells (SMCs) and that cytochrome P4501B1 (CYP1B1) plays an important role in the activation of MC to genotoxic intermediates. Methods: Cultured SMCs were treated with MC or the vehicle dimethyl sulfoxide (DMSO), and DNA was isolated after 24 h. In some experiments, the cells were pre-treated with the CYP1B1 inhibitor 1-ethynylpyrene (EP) prior to exposure to MC. DNA adducts were determined by the 32 P-postlabeling assay. Aryl hydrocarbon hydroxylase assay was measured by fluorimetry. Results: MC induced formation of 12 DNA adducts that were not observed in DMSO-treated cells. DNA adduct formation was dose-dependent, with maximum response observed at 3 mM. Pre-treatment of cells with EP dramatically suppressed DNA adduct formation by MC. MC treatment caused induction of CYP1B1, but not CYP1A1. Conclusion: The induction of high levels of multiple DNA adducts in SMCs by MC suggests that SMCs have a functional enzymatic machinery capable of metabolically activating MC to genotoxic metabolites. The significant inhibition by EP of MC-induced DNA adduct formation indicated that CYP1B1 was the primary CYP enzyme responsible for formation of genotoxic metabolites that may play a role in the induction of atherosclerosis by MC.
Introduction
induces tumors in a variety of organs in experimental animals, is also a potent atherogen in animals. Penn and Atherosclerosis, a complex and chronic disease process Snyder [5] have found that MC administration to cockerels involving elastic and muscular arteries, is the leading cause enhances atherosclerosis by 8-16-fold. In addition, MC of death in the US. A preponderance of evidence suggests initiates atherosclerosis in several mouse strains, with Ahthat cigarette smoking is potentially the most remedial responsive mice being more susceptible to atherosclerosis contributor to cardiovascular mortality and morbidity [1, 2] .
than Ah-non-responsive mice [6, 7] . The Ah-responsiveness Polycyclic aromatic hydrocarbons (PAHs) are important refers to the inducibility by PAHs such as MC and constituents of cigarette smoke, and animal and human benzo[a]pyrene (BP) of cytochrome P4501A1 (CYP1A1) studies have suggested that PAHs may be involved in the [10] , which is regulated by the Ah receptor (AHR). The etiology of atherosclerosis associated with exposure to catalytic activities of CYP1A1 are frequently determined cigarette smoking [3] [4] [5] [6] [7] [8] [9] . However, the molecular mechaby measuring the activity of aryl hydrocarbon hydroxylase nisms of vascular damage by PAHs are not understood.
(AHH), which catalyzes the conversion of BP to 3-OH-BP 3-Methylcholanthrene (MC), a potent PAH carcinogen that [11] . The induction of CYP1A involves binding of ligand to the AHR, followed by nuclear translocation and complexing of the ligand-AHR with the AHR nuclear trans-locator (ARNT). The ligand-AHR-ARNT complex interpotent inducers of the enzyme [31] . On the basis of this, acts with specific regulatory elements, i.e., Ah response we tested the hypothesis that MC can induce DNA adducts elements (AHREs) that are located in multiple copies on in mouse aortic SMCs and that CYP1B1 plays an imthe CYP1A promoter, eventually leading to augmentation portant role in the activation of MC to genotoxic metaboof gene expression [12] .
lites. The parent PAHs by themselves are non-toxic; metabolic Because AHH activity is catalyzed by CYP1A1 and activation of PAHs by CYP1A1 / 1A2 leads to the pro-CYP1B1 [23] , we used isozyme-selective inhibitors that duction of reactive metabolites capable of covalently would discriminate between the two isoforms. To this end, binding to DNA, a key event in the initiation of carcinowe used (i) ellipticine that selectively inhibits CYP1A1 genesis and / or atherogenesis [13] . While the liver CYP [32] ; (ii) a-naphthoflavone (a-NF) that inhibits both enzymes play a major role in the PAH metabolism, leading CYP1A1 [33] and CYP1B1 [34, 35] ; and (iii) 1-to transport of the metabolites to target organs, extraethynylpyrene (EP), which is specific for CYP1B1 [35, 36] , hepatic tissues are also known to contain the CYP enzymes to identify the CYP1 isoform in the vascular SMCs that is that can activate PAHs [14] . In fact, PAH-DNA adduct responsible for the metabolic activation of MC. formation has been demonstrated in several human cancer cell lines and organ explant cultures of extra-hepatic origin [15, 16] . However, PAH activation leading to DNA adduct 2. Methods formation in cultured smooth muscle cells (SMCs) of aorta, the target organ for the development of athero-2. MA, USA). All other chemicals were purchased from Several lines of evidence suggest a close parallelism Sigma unless otherwise noted. BP, MC, EP, ellipticine, and between carcinogenesis and atherogenesis, with both proa-naphthoflavone (a-NF) stock solutions were prepared in cesses involving key steps of initiation and promotion dimethyl sulfoxide (DMSO). [4, 18] . The presence of PAH-DNA adducts in atherosclerotic lesions of humans suggest that DNA adducts contribute to the development of atherosclerosis [8, 9] .
2.2. Cell culture Although CYP enzymes are known to bioactivate PAHs to DNA-binding derivatives, little progress has been made in Primary cultures of vascular SMCs were isolated from understanding the relationship between CYP-mediated female C57BL / 6 mouse aorta and maintained under PAH metabolic activation and DNA adduct formation in standard conditions as described by Ramos and Cox [37] . vascular tissue. Evidence to date has shown that BP Female mice were used because the development of mouse induces CYP1A1 in rat aortic tissues [19] , while MC model(s) of atherogenesis by MC was based on experiadministration to rabbits enhances formation of phenolic ments conducted in female mice [6, 7] . The investigation metabolites in aortic homogenates, further suggesting conforms with the Guide for Care and Use of Laboratory induction of CYP1A1 [20] . While CYP1A1 has been Animals, published by the US National Institutes of Health localized in both endothelial cells and SMCs of aorta (NIH Publication No. 85-23, revised 1996). Cells were [21, 22] , CYP1A1 is under negative regulation in adult grown in Medium 199 (Gibco, Grand Island, NY, USA) quail aortic SMCs [23] . Thus, it appears that other CYP supplemented with 10% fetal bovine serum (FBS) (Atlanta isoforms contribute to PAH metabolism in SMCs.
Biologicals, Norcross, GA, USA), 2 mM glutamine, 100 A number of CYP isoforms are expressed within the units / ml penicillin, 0.1 mg / ml streptomycin and 0.25 mg / vascular wall, including CYP1B1, whose activity can also ml amphotericin B (Gibco). Subcultures were prepared by be determined by measuring AHH [24] . This isoform is trypsinization (Gibco) of subconfluent primary cultures. 2 preferentially expressed in SMCs [25] , as opposed to Cells were seeded at 100 cells / mm onto 100 mm plates 2 vascular endothelium, and is co-expressed with CYP1A1 for AHH assays, and 75 cells / mm onto 150 mm plates for in several extra-hepatic tissues [26] . CYP1B1, which postlabeling experiments, cells were allowed to acclimatize participates in PAH metabolic activation to oxidative for 48 h, then challenged with MC, BP, EP, ellipticine or intermediates and carcinogenic precursors [27] [28] [29] [30] , has a-NF for the time periods specified in the figure legends. been implicated in atherogenesis by PAHs, which are
Concentrations of DMSO in all experiments were ,0.15%.
32
The rationale for using these concentrations was that 2.6. DNA isolation and P-postlabeling DMSO did not produce any effect on vascular SMCs.
DNA was isolated as reported previously [41] . The 32 nuclease-P1-enhanced version of the P-postlabeling 2.3. Aryl hydrocarbon hydroxylase activity assay for MC-DNA adducts was performed as reported previously [41] [42] [43] . Briefly, DNA (10 mg) was digested The methodology described by Nebert and Gelboin [38] with micrococcal nuclease (MN) (0.04 U / ml) and spleen with modifications, was used to process samples for phosphodiesterase (SPD; 0.4 mg / ml) at pH 6.0 and 37 8C measurement of AHH activity. In brief, cells were treated for 3.5 h. The DNA was then treated with nuclease P1 (0.6 in triplicate with BP, ellipticine, a-NF, or EP. In preliminmg / ml) at pH 5.0 at 37 8C for 40 min followed by labeling ary dose-range finding studies, cells were treated for 1 and 32 with [g-P]ATP (4000 Ci / mmol) and T4 polynucleotide 24 h with ellipticine (0.001-0.1 nM), a-NF (1-100 nM) kinase (0.5 U / ml) at pH 9.5 and 37 8C for 30 min. The or EP (1-1000 nM). For metabolism inhibition studies, labeled products were separated by two-dimensional polycells were treated with the CYP inhibitors ellipticine (0.1 ethyleneimine (PEI)-cellulose thin-layer chromatography nM), a-NF (10 nM), or EP (1000 nM) for 1 h prior to (2D-PEI-TLC) [43] . The 2D maps were exposed to treatment with BP (3 mM) for 24 h. Cells were washed autoradiography with intensifying screens at a typical with 1 ml ice-cold Tris-sucrose buffer (0.05 M Tris, 0.2 M exposure of 16 h at 280 8C. The adduct spots were sucrose, pH 8.0), scraped from the substrate and cenquantified by scintillation counting and expressed as trifuged (1100 rpm, 5 min, 4 8C). Supernatants were relative adduct labeling (RAL) values [42] . In order to decanted and the pellets resuspended in ice-cold Trisquantify spots that were not well separated, we subjected sucrose buffer. One-third of the sample was combined with 32 the P-postlabeled TLC maps to shorter autoradiographic 0.1 M HEPES (pH 8.0), 0.4 mM NADPH (in 1% sodium exposures (4-6 h), which showed clearer demarcation of hydrogencarbonate) in a borosilicate tube and incubated at individual spots, and then used these films as templates for 37 8C for 2 min, followed by addition of BP (3 mM in quantification. MeOH), protected from light and further incubated at 37 8C for 15 min. The reaction was stopped with ice-cold acetone and hexane, vortexed and the organic (top) layer 3. Results removed. To the organic layer, 1 M NaOH was added, vortexed and the aqueous (bottom) layer removed for Exposure of SMCs to 0.3 mM MC gave rise to 12 analysis. 3-OH BP standards were prepared in 1 M NaOH 32 P-postlabeled DNA adduct spots that were not observed and read using a spectrofluorometer prior to analysis of in cells treated with the vehicle DMSO (Fig. 1) . In cells samples (396 nm excitation, 522 nm emission). The initial treated with 0.03 mM MC, adducts 1,7,10, and 12 were not cell sample in Tris-sucrose buffer was analyzed for total formed (not shown). In SMCs exposed to 3 mM, the protein concentration by the method of Bradford [39] .
intensities of all adduct spots increased. Quantitative analyses revealed that adduct formation was dose-depen-2.4. Western blotting dent, with total adduct RAL values increasing from 2.623 8 8 10 for 0.03 mM dose to 211.95310 for the 3 mM dose CYP1A1 and 1B1 protein expression in the vascular ( Table 1) . The most marked increase in adduct values at SMCs was determined by Western blotting using CYP1A1 the highest dose was observed for spots 1, 2, 5, 6, 7, and 9, and 1B1-specific antibodies. The cell pellets described which displayed 10-15-fold induction compared to cells above were used as the protein source. Procedures for treated with a 10-fold lower dose (Table 1) . Treatment Western analysis have been described previously [40] .
with EP, a specific CYP1B1 inhibitor, followed by MC, resulted in strong inhibition (|90%) of total adducts levels 32 2.5. Cell isolation for P-postlabeling ( Fig. 2 ; Table 2 ). There were no qualitative changes in MC-DNA adduct profiles in cells pre-treated with EP 2 Vascular SMCs were seeded at 75 cells / mm in three (Fig. 2) ; however, formation of all individual adducts was separate 150 mm culture plates per treatment to generate suppressed (25-95%) ( Table 2 ) by EP. EP itself did not 7 |1310 cells. Cells were treated with DMSO (control) or induce any adducts (Fig. 2) . While adduct patterns were (0.03, 0.3, or 3 mM) MC for 24 h. Some cells were treated quite reproducible in repeat experiments, we did notice with EP (1 mM) alone or pretreated with EP (1 mM; 1 h) some variation in levels of MC-DNA adducts when prior to MC treatment. At the end of treatment, cells were quantitative data from independent experiments (Tables 1 harvested by trypsinization, centrifuged (1100 rpm, 5 min), and 2) were compared. This was probably due to a resuspended and counted in a hemocytometer. Cells were combination of inter-experimental variability in cell treat- 32 then pelleted (1100 rpm, 5 min), resuspended in 1 ml TE ments, DNA isolation, and P-postlabeling. buffer (10 mM Tris-Cl, 1 mM EDTA, pH 7.65), and stored
We tested three agents for their ability to inhibit AHH at 220 8C prior to analysis. activity, which is catalyzed by CYP1A1 as well as CYP1B1 [23] . The concentrations used for each inhibitor pretreatment dramatically inhibited hydrocarbon-inducible were based on pilot studies, and concentration ranges of AHH activity (Fig. 4) . 0.001-0.1, 1-100, and 10-1000 nM were found to be In order to confirm that MC induced CYP1B1, but not optimal for ellipticine, a-NF, and EP, respectively. Ellip-CYP1A1, in vascular SMCs, cells exposed to MC were ticine (Fig. 3A) did not significantly inactivate enzyme subjected to Western analyses. As shown in Fig. 5A , activity. However, a-NF (Fig. 3B) as well as EP (Fig. 3C) uninduced cells showed basal expression of CYP1B1, and caused a modest inhibition of the enzyme activity. We then MC (0.03 mM) treatment led to induction of CYP1B1. tested the ability of each of these agents to inhibit aryl However, at higher MC concentrations (0.3-3 mM), the hydrocarbon inducible activities, with BP as the AHH induction of CYP1B1 was not very pronounced (Fig. 5A) . inducer, since, like MC, it is a ligand for the AHR and
In cells pre-treated with EP (1 mM), followed by MC (0.3 SMCs respond well to induction by BP. As shown in Fig. mM), CYP1B1 expression was elevated, compared to those 4, BP (3 mM) treatment of SMCs caused marked induction treated with MC (0.3 mM) alone (Fig. 5A) . of AHH activity. Pre-treatment of cells with ellipticine or
In contrast, CYP1A1 was not detectable in uninduced a-NF, at the indicated concentrations, followed by BP cells or in SMCs treated with MC (Fig. 5B) . In order to challenge, did not modulate AHH activity. However, EP ensure that we are able to detect CYP1A in our experimental conditions, as a positive control we simultaneously performed Western analysis of microsomal proteins (5 mg) potent genotoxic agent in these cells and that the individual DNA isolation, and P-postlabeling were carried out as described in Methods.
adducts are derived from interaction of different ultimate genotoxic intermediates with DNA at different sites [44] . atherogenesis [18] , it is likely that DNA adduct formation Individual MC-DNA adducts have not been structurally in SMCs contributes to atherogenesis by PAHs. In fact, characterized in SMCs or other cell types, but Osborne et DNA synthesis and DNA repair in SMCs treated with al. [45] have reported that formation of syn-and anti-9,10-PAHs has recently been reported [46] . diol epoxides as ultimate carcinogenic metabolites of MC The formation of DNA adducts in SMCs indicates the in V79 cells. We reported previously [41] that MC adminispresence in these cells of a functionally active enzymatic tration to rats leads to production of multiple DNA adducts system that activates PAHs. Because CYP1 enzymes play in liver and other tissues.
important roles in the metabolic activation of PAHs, we DNA adduct formation represents a key event in initiaconducted experiments to determine the nature of CYP1 tion of carcinogenesis [13] , and, if unrepaired, could lead enzymes in SMCs. For this, we studied the effect of to gene mutations and development of tumors. Because inhibitors of AHH activities and DNA adduct formation. there is a parallelism between carcinogenesis and As shown in Fig. 3A , ellipticine, a specific inhibitor for CYP1A1 [32] , did not inhibit AHH activities in SMCs. This finding, in conjunction with the modest, but significant inhibition by EP (Fig. 3C ), a specific CYP1B1 Table 2 Effect of EP on MC-DNA adduct levels inhibitor [36] , and a-NF (Fig. 3B) , which also inhibits CYP1B1, suggests the CYP1B1 is the major CYP1 DNA isolation, and P-postlabeling were carried out as described in Methods.
h after treatment with MC, and by this time it is possible Fig. 4 . Effect of CYP inhibitors on arylhydrocarbon-inducible AHH activities. SMCs treated with DMSO, ellipticine (0.1 nM), a-NF (10 nM), or EP (1 mM) for 1 h, followed by exposure to DMSO alone or to BP (3 mM) for 24 h. AHH activity was estimated in SMCs as described in Methods. Values represent the means6S.E. of three independent experiments. *, Statistically significant differences at P,0.01.
[23] that CYP1A1 is under negative regulation in vascular SMCs.
The contribution of DNA adducts to the development of atherogenesis is not well understood. The mutation theory of atherogenesis [48] suggests that DNA adduct formation represents the initiation step of atherogenesis. While, there is close parallel between carcinogenesis and atherogenesis, the lack of mutations in the K-ras codon 12 and 13 in the DNA of SMCs isolated from abdominal aorta of human atherosclerotic lesions suggested that K-ras is not a candidate gene that contributes to atherogenesis [49] , although mutations in this gene are observed in human cancers [50] , and in lung tumors of mice exposed to MC [51] . Thus, DNA adducts may contribute to atherogenesis, and if so there may be differences in target genes that control the processes of carcinogenesis and atherogenesis. One of our laboratories has demonstrated that c-Ha-ras activation by BP is dependent on the metabolism of PAHs by CYP and that this gene contributes to atherogenesis by area are needed to study the specific mechanistic contributions of DNA adducts in PAH-induced atherogenesis.
that the induction had already declined. A recent paper [47] showing an attenuation of CYP1B1 induction 5 h after Acknowledgements treatment of SMCs with the PAH BP is consistent with this hypothesis. The increase of CYP1B1 expression in the This work was supported in part by a Grant-in-Aid EP1MC samples was likely due to induction by EP after award by the American Heart Association (Texas Affiliate) initial inhibition, as shown previously in 10T1 / 2 cells [36] .
and NIEHS 09132 from the National Institute of EnThe lack of CYP1A1 in these cells treated with MC (Fig. vironmental Health Sciences to B.M. and NIEHS 04849 to 5B) was consistent with the findings of Ou and Ramos K.S.R. SMCs were treated with DMSO or MC at the indicated concentrations and Western blotting using CYP1A1 or 1B1 antibody was performed using total cellular protein (20 mg), as described in Methods. In order to the study the effect of EP, cells were treated with 1 mM EP 1 h prior to treatment with MC (0.3 mM), and Western analysis was performed. As shown in the figure, basal and inducible CYP1B1 (A), but not CYP1A1 (B), was detectable. P.C., Positive control. A 5-mg amount of microsomal protein from livers of rats treated with MC was applied on the same gel in order to ensure that our experimental conditions were optimal for detecting CYP1A1. M, Molecular weight marker.
toxicity of 2,3,7,8-tetrachloro-p-dioxin and related compounds.
